Dear Fellow Investor, | Rare earths aren't rare in use.
They're inside phones, EVs, missiles, satellites — and AI chips. | Right now, China controls most of the supply chain.
That's the real problem. | So when the Trump administration talks about putting $1.6 billion into USA Rare Earth, it's not an investment bet. | It's an insurance policy. | For years, the U.S. let rare-earth mining and processing move overseas because it was cheaper and messy. | Now it's realizing that "cheap" comes with strings attached. | If China ever restricts exports, entire industries slow down overnight.
Defense. Energy. Tech. All exposed. | That's why Washington is stepping in — because markets alone don't rebuild strategic supply chains fast enough. | This move isn't about digging rocks.
It's about control over inputs. | No headlines. No hype. Just resilience. | And here's the part most people miss: | These assets are already American-owned at the sovereign level.
In certain cases, they can be accessed through legal, publicly traded structures. | That's what this report explains. | See your birthright "claim" and how to activate it, before it's too late | | | | | | |  | Fresh Insight for You |
|
|
|
TrumpRx: The $450 Billion Healthcare Shakeup Nobody Saw Coming |
|
|
|
You walk into your pharmacy. Hand over your discount card. |
Walk out paying $149 for a month's supply of Wegovy instead of $1,349. |
Sounds too good to be true, right? |
That's exactly what TrumpRx.gov is promising. |
So, what it is, how it works, and which healthcare companies stand to win or lose under it. |
|
What's Really Going On Here? |
|
Here's the deal. The White House just launched a website, TrumpRx.gov, that acts like a massive coupon book for prescription drugs. But it's not your grandma's coupon book.
|
| ❝ | | | "You're going to save a fortune. And this is also so good for overall health care." | | | | President Donald Trump |
|
|
This thing bypasses your insurance completely. |
You print a card. Show it at the pharmacy. Pay cash. Done. |
The focus? Those crazy-expensive weight-loss drugs everyone's talking about. Ozempic. Wegovy. Zepbound. Drugs that normally cost over a thousand bucks a month. |
|
With TrumpRx? You're looking at $149 to $299 a month. |
That's an 85% to 90% discount. Not a typo. |
| | | | Would you use TrumpRx for your prescriptions? | |
| |
| | |
|
|
How Does This Actually Work? |
|
Think of it like this. You know how there's always a middleman taking a cut? In healthcare, those middlemen are called Pharmacy Benefit Managers, PBMs for short. |
They negotiate drug prices. They take rebates. They add fees. And somewhere along the way, your $50 drug becomes $500. |
TrumpRx cuts them out entirely. |
Drug companies like Novo Nordisk $NVO ( ▲ 9.92% ) and Pfizer $PFE ( ▲ 2.76% ) agreed to sell directly to you at "most favored nation" pricing. That's government-speak for "the lowest price we charge anywhere in the world." |
Why would they do that? Two reasons. |
First, they get to bypass all those PBM fees. Second, they look like heroes. Public relations gold. |
But here's where it gets interesting. |
|
The Cash-Only Twist |
Your insurance won't cover this. Can't cover it, actually. |
It's cash only. No co-pays. No deductibles. No insurance claims. |
For some people, that's perfect. If you're uninsured or your plan doesn't cover weight-loss meds anyway, you just saved a mortgage payment every month. |
But if you have good insurance that already covers these drugs? You might be better off sticking with your current plan. |
See, once you hit your deductible, insurance usually picks up most of the tab. TrumpRx doesn't help with that. |
It's a discount program, not insurance. |
| | One crypto insight could change everything | Here's the truth about crypto wealth… | You don't need to be right 27 times. You don't even need to be right 10 times. | You need to be right once. | One coin. One trend. One insight at the right moment. | That's what changes everything. | On February 10th, 27 of crypto's most successful minds are coming together to share their strategies for 2026. We're talking founders of Tether, Solana, and THORChain revealing their exact playbook. | 27 experts. 27 chances to find the one insight that transforms your portfolio. | Normally this kind of access costs $799. | Right now, it's free. | Claim your pass to the Crypto Community Summit now (free for a limited time) | *ad |
| | |
|
|
Winners & Losers |
|
Let's talk winners first. |
Uninsured Americans are celebrating. About 27 million people in the U.S. don't have health coverage. For them, TrumpRx just made expensive medications affordable for the first time. Drug companies are smiling too. Novo Nordisk's stock jumped 4% when this launched. They're selling more drugs, cutting out middlemen, and getting positive press. Win-win-win. Retail pharmacies like Walmart and CVS? They're seeing more foot traffic. More people coming in means more impulse purchases. That candy by the register doesn't sell itself. The uninsured and underinsured finally have access. That's about 45 million Americans who might benefit.
|
Now for the losers. |
|
No middleman needed? No fees to collect. |
$CVS dropped 2% the day TrumpRx launched. That tells you everything. |
Insurance companies aren't thrilled either. If people start paying cash for drugs instead of using insurance, their negotiating power weakens. And if drug prices drop globally, they might face pressure to lower premiums.
|
But will they? History says don't hold your breath. |
Other countries might actually pay more. Drug companies have been charging Americans more to subsidize lower prices abroad. If U.S. prices drop to match international rates, companies will need to make up that revenue somewhere. |
Critics are already calling it "cost-shifting." |
|
|
What This Means |
Let's get practical. Should you use TrumpRx? |
Use it if: |
You're uninsured Your insurance doesn't cover the drug you need Your deductible is sky-high and you're paying full price anyway You're on Medicare and stuck in the donut hole
|
Skip it if: |
Your insurance already covers the drug with a low co-pay You've hit your deductible for the year Your employer plan has good drug coverage
|
Run the numbers. Compare what you'd pay with TrumpRx versus what you'd pay through insurance. |
Sometimes the discount program wins. Sometimes your insurance does. |
|
The Investment Angle |
Now, if you're thinking about where to put your money, this gets interesting. |
Pharma stocks are mixed. Companies partnering with TrumpRx (Novo Nordisk, Pfizer, Eli Lilly) are seeing volume increases. That's good for revenue. |
But gross margins are getting squeezed. Selling drugs for 90% less means less profit per pill. They're making it up in volume, but it's a different business model. |
PBM stocks are under pressure. CVS Health, Cigna, UnitedHealth—all down since the announcement. This isn't a one-day blip. It's a structural threat to their business. |
Retail pharmacy stocks are up slightly. More prescriptions filled means more revenue, even if the margins are thinner. |
The smart money is watching which companies adapt versus which ones fight this trend. |
|
The Bigger Picture |
Here's what most people are missing. |
This isn't just about cheaper drugs. It's about changing how American healthcare works. |
For decades, we've had this opaque system where nobody knows what anything really costs. Your doctor prescribes something. Your insurance "covers" it. You pay a co-pay. Nobody questions it. |
TrumpRx is bringing price transparency. You know exactly what you're paying. No surprises. No hidden fees. |
Is it perfect? No. |
Critics call it a "glorified coupon book" with limited drug selection. They're not wrong. Right now, it's mostly weight-loss drugs and a few common medications. |
But it's a start. |
If this works, expect it to expand. More drugs. More manufacturers. More savings. |
|
What Happens Next? |
The healthcare industry is watching this closely. |
If TrumpRx succeeds, other countries might launch similar programs. Competition could drive prices down even further. |
If it fails, it'll be because the middlemen fought back. PBMs have deep pockets and powerful lobbyists. They won't go quietly. |
Insurance companies might start their own discount programs to compete. That'd be ironic, insurance companies offering cash discounts that bypass insurance. |
But stranger things have happened. |
Just don't expect your insurance company to be happy about it. |
Do the math. Make the smart choice. |
Your wallet will thank you. |
|
| | | | Quick ratingHow was this one? | |
| |
| | |
|
Disclaimer: This analysis is for educational purposes only and should not be considered investment advice. Always do your own research before making investment decisions. |
Items marked with an asterisk (*) are promotional and help support this newsletter at no cost to readers. |
Tidak ada komentar:
Posting Komentar